Sam Waksal is once again in legal trouble. The biotech entrepreneur, who was famously convicted...
Author - David Miller
STAT+: Research grants as political ammo; Death to dyes?
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the...
Behind the Headlines Episode 15–Neuroscience, Weight-Loss...
Mike Exton, Andrew Thomson, Konstantinos Tsioris, and Cheryl Barton go behind the headlines to...
FDA Grants Priority Review to Regeneron’s Eylea for Macular...
Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea...
The Great RIF(T): One FDA Division’s Destruction and What it...
By Kurt R. Karst — The FDA Reduction-in-Force (Termination)—or “RIF(T)”—announced last...
New CDMO Meribel Pharma Solutions Launches with 13 Sites in...
The new United Kingdom-based firm has sites located in France, Spain, and Sweden, thanks to an...
Regeneron, Sanofi Get FDA Approval for Dupixent to Treat Chronic...
Dupixent is the first new targeted therapy to receive FDA-approval for chronic spontaneous...
Using RWD to Create Personalized Engagement
Ted Sweetser discusses how more accurate datasets are solving problems related to getting...
More on the Impact of the FDA RIFs: How Information Disclosure...
By Sarah Wicks & Anne K. Walsh — The recent and drastic Reduction In Force (RIF) at the U. S...
STAT+: Women’s Health Initiative, known for hormone therapy...
Federal funding for the Women’s Health Initiative, which as one of the largest research projects...